GlassScriptPhysician profile
Anna Farnan
NPI 1427814664
$3,486.41
in general payments reported to CMS, 2019-2025
26 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,645 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $365.72 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Eisai INC. | $362.02 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $280.73 | 2024-2025 | |
| Lilly USA, LLC | $278.02 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Abbvie INC. | $264.99 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $262.39 | 2024-2025 | Ingrezza |
| Csl Behring | $226.33 | 2024-2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $176.78 | 2024 | Ultomiris |
| Neurelis, INC. | $157.59 | 2024-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $134.25 | 2024-2025 | Crexont, Rytary, Ongentys |
| Sk Life Science, INC. | $108.54 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $94.04 | 2024-2025 | Wainua |
| Acadia Pharmaceuticals INC | $82.62 | 2024-2025 | Nuplazid |
| Springworks Therapeutics, INC. | $81.85 | 2025 | Gomekli |
| Biogen, INC. | $76.28 | 2024-2025 | Vumerity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $75.77 | 2024-2025 | Vyepti |
| Genentech USA, INC. | $71.79 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $65.54 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Argenx US, INC. | $56.27 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $45.22 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $44.98 | 2025 | Xeomin, Inbrija, Ampyra |
| Amgen INC. | $43.28 | 2025 | Uplizna |
| Scilex Pharmaceuticals INC. | $42.32 | 2025 | |
| Tanabe Pharma America, INC. | $39.32 | 2024 | |
| Harmony Biosciences LLC | $35.12 | 2024 | |
| Pfizer INC. | $14.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Farnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.